Girish Sanktha Prasad Mishra

Girish Sanktha Prasad Mishra

Active Director Director DIN 07723590
DIN 07723590 First appointment Apr 2017 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 2 historical roles
Total affiliations 5 Since Apr 2017
Shareholding value •••• Premium profile

About Girish Sanktha Prasad Mishra

Data last updated:

Girish Sanktha Prasad Mishra is a Director at Safelife Pharma Speciality Private Limited (since 2018), Director at Association Of Advanced Learners In Medicine (since 2018) and Director at Sarvabhav Foundation (since 2021). The companies operate in Pharma, Education & Learing and Non-Profit Organizations. The 2 current companies with reported revenue have a combined latest revenue of ₹15.47 Cr; the largest is Safelife Pharma Speciality Private Limited at ₹13.73 Cr (FY 2024). Earlier, Girish Sanktha Prasad Mishra was a Director at Momed Drugs Private Limited (2017–2019) and Additional Director at Mehi Medical Education And Healthcare Institute Private Limited (from 2018).

DIN 07723590
Primary Designation Director
Industry Pharma
First Appointment 05 Apr 2017
Oldest Company Age 12 yrs
Largest company Safelife Pharma Speciality Private Limited · ₹13.73 Cr (FY 2024)
Combined revenue ₹15.47 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director03 Mar 20182016₹13.73 Cr (FY 2024)Active
Director08 Jun 20182018₹1.74 Cr (FY 2019)Active
Sarvabhav Foundation U85320GJ2017NPL096477
Director01 Feb 20212017Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Momed Drugs Private Limited U51909MH2017PTC293424
Director05 Apr 20172017Active
Additional Director08 Jan 20182014Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Mehi Medical Education And Healthcare Institute Private Limited
Safelife Pharma Speciality Private Limited
Association Of Advanced Learners In Medicine
Sarvabhav Foundation
Premium access

Shareholding and investment profile for Girish Sanktha Prasad Mishra

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Girish Sanktha Prasad Mishra

Girish Sanktha Prasad Mishra currently holds 3 directorships: Safelife Pharma Speciality Private Limited (Director, since 03 Mar 2018, revenue ₹13.73 Cr (FY 2024)); Association Of Advanced Learners In Medicine (Director, since 08 Jun 2018, revenue ₹1.74 Cr (FY 2019)); Sarvabhav Foundation (Director, since 01 Feb 2021).

Girish Sanktha Prasad Mishra was first appointed on 05 Apr 2017 as Director at Momed Drugs Private Limited. The most recent appointment on record is 01 Feb 2021 at Sarvabhav Foundation.

The 2 current companies of Girish Sanktha Prasad Mishra that report revenue have a combined latest revenue of ₹15.47 Cr: Safelife Pharma Speciality Private Limited ₹13.73 Cr (FY 2024); Association Of Advanced Learners In Medicine ₹1.74 Cr (FY 2019).

Girish Sanktha Prasad Mishra held 2 earlier board appointments: Momed Drugs Private Limited (Director, 05 Apr 2017 to 11 Mar 2019); Mehi Medical Education And Healthcare Institute Private Limited (Additional Director, from 08 Jan 2018).

The current boards of Girish Sanktha Prasad Mishra's companies include Sandeep Sankatha Mishra (Safelife Pharma Speciality Private Limited), Shubha Girish Mishra (Safelife Pharma Speciality Private Limited), Harshnandan Nandlal Trivedi (Association Of Advanced Learners In Medicine).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available